Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.37 |
| ▸ | MLNR | O43193 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9666911 | 1.00 | CAPN1 (0.39) | CAPN1GAACXCR4ITGB1ITGA4 | |
| SCHEMBL9666919 | 1.00 | CAPN1 (0.39) | CAPN1GAACXCR4ITGB1ITGA4 | |
| SCHEMBL9479076 | 0.85 | HRH3 (0.45) | GAAHRH3 | |
| SCHEMBL8102895 | 0.85 | HRH3 (0.45) | GAAHRH3 | |
| SCHEMBL6753882 | 0.85 | HRH3 (0.45) | GAAHRH3 | |
| SCHEMBL9666858 | 0.85 | HRH3 (0.45) | GAAHRH3 | |
| SCHEMBL9665668 | 0.85 | HRH3 (0.45) | GAAHRH3 | |
| SCHEMBL8102889 | 0.85 | HRH3 (0.45) | GAAHRH3 | |
| SCHEMBL9478999 | 0.84 | — | — | |
| SCHEMBL9666883 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | claimed |
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | disclosed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | LNPEP, ANPEP, DNPEP | CAPN1 1195/4885GAA 1465/4885CXCR4 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.